TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
INVO Fertility ( (IVF) ) just unveiled an announcement.
On August 21, 2025, INVO Fertility, Inc. and Five Narrow Lane LP amended their financial agreement, reducing the principal amount of a debenture and exchanging it for preferred stock shares. Additionally, they extended deadlines for filing and effectiveness of a registration statement with the SEC, impacting the company’s financial operations and stakeholder interests.
The most recent analyst rating on (IVF) stock is a Sell with a $1.50 price target. To see the full list of analyst forecasts on INVO Fertility stock, see the IVF Stock Forecast page.
Spark’s Take on IVF Stock
According to Spark, TipRanks’ AI Analyst, IVF is a Underperform.
The overall stock score is primarily impacted by poor financial performance and bearish technical indicators. The company’s significant operational losses and high leverage pose substantial risks. The negative P/E ratio and lack of dividend yield further weaken the valuation. Despite a positive corporate event, the overall outlook remains challenging.
To see Spark’s full report on IVF stock, click here.
More about INVO Fertility
INVO Fertility, Inc. operates in the fertility industry, focusing on providing innovative fertility treatment solutions. The company is known for its INVOcell technology, which offers a more natural and affordable option for assisted reproductive procedures.
Average Trading Volume: 1,516,348
Technical Sentiment Signal: Sell
Current Market Cap: $4.8M
See more insights into IVF stock on TipRanks’ Stock Analysis page.